How AstraZeneca plc Will Deliver Its Dividend

What can investors expect from AstraZeneca plc (LON:AZN)’s dividend?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m looking at some of your favourite FTSE 100 companies and examining how each will deliver their dividends. Today, I’m putting pharmaceuticals firm AstraZeneca (LSE: AZN) (NYSE: AZN.US) under the microscope.

Dividend policy

Let’s track AstraZeneca’s shifting dividend policy from 2008. During 2008 the board reaffirmed its existing policy:

“To grow dividends in line with reported earnings before restructuring and synergy costs, with an aim to maintain at least two times dividend cover”.

The following year, the policy was amended. Where previously the policy had been to “grow” the dividend, the board said it now intended to maintain or grow” (my emphasis) the dividend.

The policy was amended again when AstraZeneca announced its first-half results for 2012. Where previously the policy had been to “maintain at least two times dividend cover”, the board said the dividend would no longer reflect the financial performance of “a single year taken in isolation”, and that the new target would be “an average dividend cover of 2 times” (my emphasis) over “the entirety of the investment cycle”.

To borrow a phrase from legendary investor Warren Buffett, it looks like a case of management “tempted to shoot the arrow of performance and then paint the bull’s-eye around wherever it lands”.

Implications

Bringing the dividend growth target down to as low as 0% gave the board the option of retaining as much cash as possible within the company without actually cutting the dividend. For 2012 the board held the dividend at the 2011 level, and this year’s first-half dividend, announced last week, has also been held flat. The consensus forecast among City analysts is for no growth in the payout this year or next.

Clearly, management decided that lowering the dividend-payout bar to a maintained dividend was not enough. A change was also needed to the dividend-cover policy in order for the board to be able to say of future dividends that they are in accordance with company policy. If AstraZeneca maintains its dividend at the current level, analyst earnings forecasts suggest dividend cover will fall to 1.9 for 2013 and 1.7 for 2014.

Behind the shifting dividend policy is the fact that the company is in transition between exclusivity losses on some of its bestselling drugs and new product launches.

Falling dividend cover means management is sailing closer to the wind with the dividend … but not so close that the payout is under any threat in the near term: forecasts suggest the company can cope with falling earnings for a few years yet. Furthermore, there’s an emergency generator in place as a result of AstraZeneca’s low net gearing of 10%. There’s scope for the company to borrow money to further support the dividend if necessary.

In summary, management would have to get things very wrong for quite a number of years before earnings and the balance sheet could no longer sustain the dividend.

Finally, I can tell you that one of the UK’s most successful investors has backed AstraZeneca to the hilt. City supremo Neil Woodford has made the company a top holding in his funds with a high-conviction weighting of 9%.

If you’re interested in discovering Woodford’s other big blue-chip bets and gaining a valuable insight into his enormously successful approach to investing, I recommend you download this free Motley Fool report.

This exclusive report is available for a limited time only, but you can download it right now — simply click here.

> G A Chester does not own any shares mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Up 75% in 5 years, I reckon this FTSE 250 still has lots to give!

Our writer explains why this FTSE 250 stock could still continue to provide growth and returns despite already being on…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 high-quality FTSE 250 stocks to consider buying

The FTSE 250 is home to some of the best investment opportunities out there. This Fool highlights two stocks for…

Read more »

Investing Articles

The Marks and Spencer share price dips! Is this my chance to buy?

Marks and Spencer was one of the hottest stocks on the market last year. With its share price falling in…

Read more »

Growth Shares

How low could the boohoo share price go?

Jon Smith explains why the enterprise value and the low risk of bankruptcy should help to prevent the boohoo share…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Down 23% in a year! Can the Diageo share price regain £30 in 2024?

This Fool UK writer is checking the charts to see if the Diageo share price can recover from the recent…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

I wouldn’t touch this FTSE 100 stalwart with a bargepole

Despite looking like a bargain on paper, this Fool is avoiding FTSE 100 constituent Vodafone at all costs. Here he…

Read more »

Investing Articles

I’m waiting for the Rolls-Royce share price to pull back before I buy

The Rolls-Royce share price has been the Footsie's best performer in the last year. But this Fool has no intention…

Read more »

Front view photo of a woman using digital tablet in London
Dividend Shares

2 dividend stocks to take me from £0 to £9.5k in second income

Jon Smith talks through some ideas with second income potential, including one stock that has a dividend yield above 10%…

Read more »